CASE REPORT

A hidden cause of oxalate nephropathy: a case report

Tala Mahmoud1, Elias C. Ghandour2,3 and Bernard G. Jaar2,3,4,5*

Abstract

Background: Oxalate nephropathy is a rare disorder that can result in acute kidney injury (AKI) and progresses to end-stage kidney disease (ESKD). The causes can be either primary or secondary. Primary hyperoxaluria includes a group of hereditary disorders with enzymatic defects in the glyoxylate pathway, resulting in decreased oxalate metabolism. Secondary hyperoxaluria, often overlooked, can result from increased intestinal absorption, nutritional deficiencies, decreased fluid intake, impaired excretion, and increased dietary consumption of oxalate.

Case presentation: We present a Caucasian case of acute oxalate-induced nephropathy associated with consumption of large quantities of green vegetables in a patient with chronic kidney disease (CKD). Imaging study showed no evidence of kidney stone, but a kidney biopsy revealed acute tubular injury, tubular atrophy, interstitial fibrosis, and dense tubular deposition of calcium oxalate crystals. Upon further questioning the patient, we learned that in the months prior to presentation, he had very significantly increased his consumption of green vegetables. Because of no clinical improvement, the patient was initiated and maintained on hemodialysis.

Conclusion: This report illustrates a case of acute oxalate nephropathy in the setting of very high dietary consumption of oxalate-rich foods in a patient with advanced CKD. Special attention should be given to the secondary causes of hyperoxaluria in patients with predisposing conditions such as CKD.

Keywords: Oxalate, Oxalosis, Hyperoxaluria, Chronic kidney disease, End-stage kidney disease, Acute kidney injury, Nephrolithiasis, Diet, Vegetables

Background

Oxalate is a simple dicarboxylic acid, often found in a variety of plants and leafy vegetables [1]. It is produced exogenously from consumption of oxalate-rich foods or endogenously from the breakdown of ascorbic acid and amino acids [2]. Major dietary sources of oxalate include leafy green vegetables (e.g., spinach), chocolate, rhubarb, beets, chard, tea, nuts and wheat bran [3]. The absorption of oxalate occurs in the stomach, small intestine and large intestine, mediated by both paracellular and transcellular reuptake [4]. Excretion of absorbed and endogenously produced oxalate occurs in the urine in an unchanged manner due to insignificant metabolism in the human body [1]. Several factors may affect the absorption and excretion of oxalate, contributing to the development of hyperoxaluria. The presence of excess oxalate in the urine may lead to the development of nephrocalcinosis, nephrolithiasis or oxalate nephropathy [5]. Here, we report a case of biopsy-proven acute oxalate nephropathy.

Case presentation

A 78-year-old Caucasian man with underlying Alzheimer’s disease presented to the emergency department with a serum creatinine level of 6.52 mg/dL from a baseline value of 1.9 mg/dL 3 months prior to presentation. Patient had a known history of benign prostatic hypertrophy with elevated post-void residual volume, thus in the emergency department a Foley catheter...
was placed to rule out obstructive uropathy. He also had previously experienced left hydronephrosis due to nephrolithiasis which were secondary to calcium oxalate, and he underwent lithotripsy at that time. A bedside kidney ultrasound performed in the emergency department showed no stone or hydronephrosis.

According to his wife, the patient had poor appetite but was reportedly consuming adequate amounts of liquids. The patient’s blood pressure was also monitored at home and there were no reports of hypotension. The patient has not had episodes of nausea, vomiting or diarrhea. There had been no consumption of nonsteroidal anti-inflammatory drugs, and no new medications were recently added. He had no malabsorptive symptoms and no gastro-intestinal surgeries. He had no family history of kidney disease or kidney stones.

Physical examination was unremarkable. Laboratory data were obtained and on presentation, the patient’s serum creatinine concentration was 6.52 mg/dL, corresponding to an estimated glomerular filtration rate (GFR) of 7 mL/min/1.73 m² from a baseline of 34 mL/min/1.73 m² (Table 1). Urinalysis showed hazy yellow urine with occasional bacteria and moderately increased proteinuria (100 mg/dL). The patient was admitted to the hospital for further evaluation and management of his AKI on CKD. A serological work-up was performed and results were unrevealing. Further, urine and serum electrophoresis showed no monoclonal gammopathy. In addition, and to avoid further calcium load, calcium acetate was discontinued, and the patient was started on IV fluid hydration and oral Sevelamer carbonate 800 mg taken with each meal for his hyperphosphatemia.

To better understand the cause of the patient's AKI, a left sided kidney biopsy was performed. Light microscopy showed numerous colorless, birefringent intratubular crystals, consistent with calcium oxalate associated with focal edema and tubular injury and mixed interstitial inflammation. Tubular atrophy and interstitial fibrosis involved 50% of the cortex and 8 of 26 glomeruli were obsolescent with focal periglomerular fibrosis on light microscopy (Fig. 1a, b). Immunofluorescence revealed non-specific staining of tubular and glomerular membranes for albumin, immunoglobulin G, kappa and lambda light chains. Electron microscopy showed variable and irregular thickening of the glomerular basement membranes, consistent with ischemic change. Loss of brush border was also noted. A diagnosis of acute tubular injury with extensive calcium oxalate crystal deposition was made.

Following the kidney biopsy findings, we further inquired about the patient’s diet, and found that several weeks prior to his illness, the patient started consuming a larger amount of leafy green vegetables than usual.

Table 1. Basic metabolic panel and complete blood count on day of admission

| Result          | Units         | Units   |
|-----------------|---------------|---------|
| Sodium          | 129           | mEq/L   |
| Potassium       | 4.4           | mEq/L   |
| Chloride        | 97            | mEq/L   |
| Bicarbonate     | 21            | mEq/L   |
| Blood urea nitrogen | 55          | mg/dL   |
| Creatinine      | 6.52          | mg/dL   |
| Estimated GFR   | 7             | mL/min/1.73 m² |
| Glucose, random | 144           | mg/dL   |
| Calcium         | 8.2           | mg/dL   |
| Phosphorus      | 5.5           | mg/dL   |
| Albumin         | 3.6           | g/dL    |
| Creatine kinase | 144           | units/L |
| Hemoglobin      | 10.3          | g/dL    |
| Hematocrit      | 30.1          | %       |
| Leukocytes      | 6.5           | 10^9/L  |
| Platelet count  | 161           | 10^9/L  |

Fig. 1a Periodic Acid-Schiff (PAS) stain magnification 400× — acute tubular injury. b Hematoxylin eosin stain magnification 200× — Oxalate crystals under polarized light
The patient had significantly increased his consumption of leafy green vegetables and was not aware of the excess level of oxalate present in his diet. This might explain a much higher source of dietary oxalate compared to his regular prior diet and could be the cause of his oxalate nephropathy given the absence of other explanations for his worsening kidney function. The patient was advised to drink plenty of fluids and avoid any nephrotoxic agents (such as IV contrast dye, aminoglycosides, and nonsteroidal anti-inflammatory drugs). He was also maintained on IV hydration. However, despite medical management, the patient’s kidney function continued to deteriorate. Therefore, the decision was made to start the patient on hemodialysis. The initiation of hemodialysis on day 5 after admission resulted in an improvement of the renal function tests. Hemodialysis was then held for a period to check for any evidence of renal function recovery. However, the patient’s kidney function continued to worsen and thus the decision was made to maintain the patient on hemodialysis.

**Discussion**

Our patient was found to have extensive calcium oxalate crystals deposition in addition to acute tubular injury. He required initiation of intermittent hemodialysis as he showed no signs of kidney function recovery. The causes of hyperoxaluria can be primary or secondary. Primary hyperoxalurias are a group of rare autosomal recessive (AR) disorders of glyoxylate metabolism, resulting in overproduction of oxalate. Primary Hyperoxaluria type 1, the most severe form, is caused by a deficiency in alanine-glyoxylate aminotransferase (AGT), a liver-specific peroxisomal enzyme responsible for the transamination of glyoxylate to glycine. Primary Hyperoxaluria type 2, a less severe form, is caused by a deficiency in glyoxylate reductase-hydroxyprolylreductase (GRHPR), a primarily intrahepatic enzyme responsible for the reduction of glyoxylate to glycolate and hydroxyproline to D-glycerate. Primary Hyperoxaluria type 3, the least severe form, is caused by a deficiency in 4-hydroxy-2-oxo-glutarate aldolase (HOGA), a liver specific mitochondrial enzyme responsible for metabolism of hydroxyproline [6, 7]. Primary hyperoxaluria can occur at almost any age, ranging from birth until the sixth decade of life [6]. However, the median age of onset is 5.5 years [8]. The clinical manifestations range from nephrocalcinosis during infancy to occasional stone formation during adulthood and diagnosis is established by genetic testing [6].

Supportive management includes increasing fluid intake, decreasing oxalate in the diet, urine alkalization, and taking calcium binders that reduce precipitation of calcium oxalate stones [7, 9, 10]. Pyridoxine was found to be beneficial in patients with Primary Hyperoxaluria type 1, through reducing excretion of urinary oxalate [11]. Definite curative treatment in Primary Hyperoxaluria type 1 patients is combined liver/kidney transplantation; however, the role of liver transplantation in patients with Primary Hyperoxaluria type 2 is still unclear. Pre-emptive combined liver and kidney transplantation should be considered in Primary Hyperoxaluria patients with GFR less than 30 mL/min per 1.73 m² [12].

In contrast, secondary hyperoxaluria may occur due to increased absorption of oxalate, nutritional deficiencies, decreased oxalate excretion, or increased dietary oxalate consumption.

The first mechanism leading to secondary hyperoxaluria is enteric hyperoxaluria. Dietary calcium normally binds to oxalate in the intestines. In the setting of fat malabsorption, calcium is sequestered by the luminal fat, resulting in increased free oxalate in the intestines and thus increased reabsorption [13]. This can arise in patients with a history of bariatric surgery, pancreatic insufficiency, crohn’s disease, celiac sprue, cystic fibrosis, orlistat and octreotide use, and *Clostridioides difficile* colitis [14–21]. The second mechanism leading to secondary hyperoxaluria is nutritional deficiencies. Thiamine and pyridoxine are essential cofactors in the glyoxylate pathway, and a deficiency results in increased oxalate formation [22]. The third mechanism occurs in the setting of significantly decreased fluid intake. Lower fluid intake leads to lower urine output, hence promoting the formation of oxalate stones through increased concentration of urine oxalate. The fourth mechanism is decreased oxalate excretion. In chronic kidney disease, lower GFR is associated with elevated plasma oxalate levels [23]. The degree of kidney function impairment is often correlated with the serum oxalate concentration [24].

### Table 2 Trend in renal function panel

| Time from admission | Day 4 | Day 5 (First hemodialysis session) | Day 6 | Day 14 (Second hemodialysis session) | Day 18 |
|---------------------|------|----------------------------------|------|------------------------------------|------|
| Blood urea nitrogen (mg/dL) | 86   | 92                               | 59   | 90                                | 70   |
| Estimated GFR (mL/min/1.73 m²) | 5    | 5                                | 8    | 5                                 | 6    |
| Creatinine (mg/dL) | 8.67 | 8.88                             | 6.28 | 8.98                              | 8.10 |

*GFR* Glomerular filtration rate
because oxalate is removed from the body almost entirely by glomerular filtration and by secretion at the level of the proximal tubule [25–30]. When plasma oxalate level exceeds its plasma supersaturation level of 30 μmol/L, this results in its deposition in several extra-renal tissues, including: retina, myocardium, blood vessel walls, bone, skin and central nervous system [5]. Finally, increased dietary oxalate may lead to secondary hyperoxaluria, particularly in patients with underlying CKD. Oxalate is present in a wide variety of leafy green vegetables and fruits. Table 3 includes a list of common foods high in oxalate. In addition, vitamin C and ethylene glycol are important sources of oxalate precursors. Recent studies suggest that about 50% of urinary oxalate is derived from the diet [31, 32]. Dietary oxalate is absorbed in the intestines by SLC26 family of transporters, via both paracellular and transcellular pathways [33]. The intestinal absorption of oxalate is affected by the bioavailability of the ingested oxalate [34].

Management of secondary hyperoxaluria involves: (1) maintaining a low-oxalate and high-calcium diet, which helps prevent hyperoxaluria, (2) increasing fluid intake (>3 L/1.73 m²), (3) supplementation with calcium or other oxalate binders and bile acid sequestrants, which decreases permeability of oxalate in the intestines, (4) consumption of probiotics that contain oxalate-degrading bacteria, however recent studies have not proven its definite efficacy [12, 35].

The disease spectrum of hyperoxaluria ranges from nephrocalcinosis, nephrolithiasis to oxalate nephropathy. Nephrocalcinosis and nephrolithiasis may remain asymptomatic, with slow CKD progression, often discovered incidentally on radiographic imaging. Acute oxalate nephropathy is characterized by AKI and often progresses to ESKD. In such event, renal replacement therapy may be required and if concern for primary hyperoxaluria is present, combined liver and kidney transplantations may need to be considered [5, 36, 37].

Conclusion
In summary, our patient with underlying CKD (stage G3B) developed acute oxalate nephropathy leading to ESKD from secondary oxalosis due to excessive consumption of oxalate-rich foods and likely decreased fluid intake. Patients with predisposing conditions such as CKD have a higher risk of developing oxalate-induced nephropathy. In addition, our case illustrates the importance of a kidney biopsy in determining the etiology of AKI when the etiology remains elusive. Therefore, in addition to the typical work-up, special attention should be warranted to the dietary habits of patients at high risk, such as those with underlying CKD.

Table 3 Oxalate content (mg/100 g) in some common foods [3]

| Food          | mg/100 g |
|---------------|----------|
| Tea           | 1150     |
| Spinach       | 970      |
| Rhubarb (raw)| 805      |
| Cocoa         | 700      |
| Beet leaves   | 610      |
| Rhubarb (stewed) | 460   |
| Red beetroot  | 275      |
| Parsley       | 170      |
| Coffee        | 100      |
| Potato        | 80       |
| Cabbage       | 60       |
| Blackcurrant  | 50       |
| Tomato        | 20       |
| Apple         | 15       |
| Lettuce       | 12       |

Abbreviations
CKD: Chronic kidney disease; ESKD: End-stage kidney disease; AKI: Acute kidney injury; GFR: Glomerular filtration rate; AGT: Alanine-glyoxylate aminotransferase; GRHPR: Glyoxylate reductase-hydroxypyruvate reductase; HOGA: 4-Hydroxy-2-oxo-glutarate aldolase.

Acknowledgements
The authors gratefully acknowledge the assistance of Dr. Serena Bagnasco who provided the renal biopsy images for our index patient.

Authors’ contributions
ECG was involved in the care of the patient. TM completed the literature search for the topic. TM and BGJ drafted and edited the manuscript. All authors read and approved the final manuscript.

Funding
No funding was needed to report this case.

Availability of data and materials
Not applicable.

Ethics approval and consent to participate
At our institution, institutional review board approval is not required for a single case report.

Consent for publication
Written informed consent was obtained from the patient’s spouse (patient is deceased) for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.

Competing interests
The authors declare that they have no competing interests.

Author details
1 Faculty of Medicine, University of Balamand, El-Koura, Lebanon. 2 Department of Medicine, Division of Nephrology, Johns Hopkins School of Medicine, Baltimore, MD, USA. 3 Nephrology Center of Maryland, Baltimore, MD, USA. 4 Welch Center for Prevention, Epidemiology and Clinical Research, Johns Hopkins University, Baltimore, MD, USA. 5 Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
References
1. Williams HE. Oxalic acid and the hyperoxaluric syndromes. Kidney Int. 1978;13(S):410–7.
2. Thompson CS, Weinman EJ. The significance of oxalate in renal failure. Am J Kidney Dis. 1984;4:97–100.
3. Noonan SC, Savage GP. Oxalate content of foods and its effect on humans. Asia Pac J Clin Nutr. 1999;8:64–74.
4. Hatch M, Freel RW. Intestinal transport of an obdurate anion: oxalate. Urol Res. 2005;33:1–16.
5. Karaolanis G, Lionaki S, Moris D, et al. Secondary hyperoxaluria: a risk factor for kidney stone formation and renal failure in native kidneys and renal grafts. Transplant Rev (Orlando). 2014;28:182–7.
6. Cochat P, Rumsby G. Primary hyperoxaluria. N Engl J Med. 2013;369:49–58.
7. Hoppe B. An update on primary hyperoxaluria. Nat Rev Nephrol. 2012;8:467–75.
8. Lieske JC, Monico CG, Holmes WS, et al. International registry for primary hyperoxaluria. Am J Nephrol. 2005;25:290–6.
9. Cochat P, Hulton SA, Acquaviva C, et al. Primary hyperoxaluria Type 1: indications for screening and guidance for diagnosis and treatment. Nephrol Dial Transplant. 2012;27:1729–36.
10. Leumann E, Hoppe B, Neuhaus T. Management of primary hyperoxaluria: efficacy of oral citrate administration. Pediatr Nephrol. 1993;7:207–11.
11. Milliner DS, Eickhoff JT, Bergstrahl EJ, et al. Results of long-term treatment with orthophosphate and pyridoxine in patients with primary hyperoxaluria. N Engl J Med. 1994;331:1553–8.
12. Hoppe B, Beck BB, Milliner DS. The primary hyperoxalurias. Kidney Int. 2009;75:1264–71.
13. Robijn B, Hoppe B, Vervaet BA, et al. Hyperoxaluria: a gut-kidney axis? Kidney Int. 2011;80:1146–58.
14. Whitson JM, Stackhouse GB, Stoller ML. Hyperoxaluria after modern bariatric surgery: case series and literature review. Int Urol Nephrol. 2010;42:369–74.
15. Carter Y, Faguer S, Karras A, et al. Oxalate nephropathy associated with chronic pancreatitis. Clin J Am Soc Nephrol. 2011;6:1895–902.
16. Siener R, Pezzold J, Bitterlich N, et al. Determinants of urolithiasis in patients with intestinal fat malabsorption. Urology. 2011;81:17–24.
17. Gibney EM, Goldfarb DS. The association of nephrolithiasis with cystic fibrosis. Am J Kidney Dis. 2003;42:1–11.
18. Allen A, Clutterbuck E, Maimdgen G, et al. Enteric hyperoxaluria and renal failure associated with lymphangiectasia. Nephral Dial Transplant. 1997;12:802–6.
19. Dossabhoy NR, McRight S, Sangha B, et al. Oralstat-induced oxalate nephropathy may be dose-independent and present as a late manifestation. J La State Med Soc. 2013;165:283–5.
20. Gariani K, de Seigneux S, Courbebaise M, et al. Oxalate nephropathy induced by octreotide treatment for acromegaly: a case report. J Med Case Rep. 2012;6:215.
21. Cohen-Bucay A, Garimella P, Ezeokonkwo C, et al. Acute oxalate nephropathy associated with Clostridium difficile colitis. Am J Kidney Dis. 2014;63:113–8.
22. Siener R, Ebert D, Nicolay C, et al. Dietary risk factors for hyperoxaluria in calcium oxalate stone formers. Kidney Int. 2003;63:1037–43.
23. Constable AR, Joeskes AM, Kasidas GP, et al. Plasma level and renal clearance of oxalate in normal subjects and in patients with primary hyperoxaluria or chronic renal failure or both. Clin Sci (Lond). 1979;56:299–304.
24. Carthy C, Faguer S, Karras A, et al. Determination of oxalic acid clearance and plasma concentration by radioisotope infusion. Results in a family with hyperoxaluria. Acta Med Scand. 1981;209:87–91.
25. Weinman EJ, Franklin SJ, Ince A, et al. Renal tubular transport of organic acids. Studies with oxalate and para-aminobenzoate in the rat. J Clin Invest. 1978;61:801–6.
26. Prenen JAC, Boer P, Dorhout Mees EJ, et al. Oxalate secretion in the rat proximal tubule. Am J Physiol. 1981;243:F271–5.
27. Holmes RP, Goodman HO, Assimos DG. Contribution of dietary oxalate to urinary oxalate excretion. Kidney Int. 2001;59:270–6.
28. Khan SR, Glenton PA, Byer KJ. Dietary oxalate and calcium oxalate nephrolithiasis. J Urol. 2007;178:2191–6.
29. Mitchell T, Kumar P, Reddy T, et al. Dietary oxalate and kidney stone formation. Am J Physiol Renal Physiol. 2019;316:F409–13.
30. Kumar R, Lieske JC, Collazo-Clavell ML, et al. Fat malabsorption and increased intestinal oxalate absorption are common after Roux-en-Y gastric bypass surgery. Surgery. 2011;149:641–4.
31. Stepień KM, Prinsloo P, Hitch T, et al. Acute renal failure, microangiopathic haemolytic anaemia, and secondary oxalosis in a young female patient. Int J Acids. 2011;63:113–8.
32. Detry O, Hononcé P, DeRoover A, et al. Reversal of oxalosis cardiomyopathy after combined liver and kidney transplantation. Transplant Int. 2002;15:50–2.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:
• fast, convenient online submission
• thorough peer review by experienced researchers in your field
• rapid publication on acceptance
• support for research data, including large and complex data types
• gold Open Access which fosters wider collaboration and increased citations
• maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more: biomedcentral.com/submissions